BSE: 524742 | NSE: CAPLIPOINT | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Caplin Point Laboratories Ltd is a average quality company.
The key valuation ratios of Caplin Point Laboratories Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Caplin Point Laboratories Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Jun'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 71.1% | 55.4% | 69% | 64.1% | 45.6% | 33.4% | 28.8% | 28.8% | 26.9% | 26.9% | - |
| Value Creation Index ⓘ | 4.1 | 3.0 | 3.9 | 3.6 | 2.3 | 1.4 | 1.1 | 1.1 | 1.0 | 1.0 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 252 | 318 | 402 | 540 | 649 | 863 | 1,061 | 1,269 | 1,467 | 1,694 | 1,831 |
| Sales YoY Gr. | - | 26.4% | 26.2% | 34.4% | 20.2% | 33.1% | 23% | 19.6% | 15.5% | 15.5% | - |
| Adj EPS ⓘ | 5.7 | 8.4 | 12.4 | 18.6 | 22.3 | 25.9 | 32.4 | 38.6 | 48.5 | 59.2 | 64.9 |
| YoY Gr. | - | 48.5% | 46.9% | 50.2% | 20% | 16.1% | 25.2% | 18.9% | 25.7% | 22.1% | - |
| BVPS (₹) ⓘ | 11.8 | 21.7 | 29.7 | 47.7 | 78 | 114.2 | 144.9 | 183.9 | 235.9 | 293.2 | 334.5 |
| Adj Net Profit ⓘ | 42.9 | 63.6 | 93.5 | 141 | 169 | 196 | 245 | 292 | 367 | 449 | 493 |
| Cash Flow from Ops. ⓘ | 49.9 | 56.5 | 67.6 | 66.5 | 83.4 | 44.7 | 269 | 337 | 271 | 318 | - |
| Debt/CF from Ops. ⓘ | 0 | 0.1 | 0 | 0 | 0 | 0.8 | 0.1 | 0 | 0 | 0 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 23.6% | 21.2% | 16.9% | 15.5% | ||||
| Adj EPS ⓘ | 29.8% | 21.6% | 22.2% | 22.1% | ||||
| BVPSⓘ | 42.9% | 30.3% | 26.5% | 24.3% | ||||
| Share Price | 36.8% | 44.7% | 32.1% | 55.5% | ||||
Performance Ratio Colour Code Guide ⓘ
| Jun'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 55.3 | 43.1 | 53 | 47.7 | 33.8 | 24.8 | 23 | 21.9 | 21.8 | 21.4 | 20.7 |
| Op. Profit Mgn % ⓘ | 24.8 | 28.1 | 31.2 | 36.2 | 35.7 | 30.1 | 31 | 31.1 | 30.1 | 32.6 | 33 |
| Net Profit Mgn % ⓘ | 17.1 | 20 | 23.3 | 26 | 26 | 22.7 | 24 | 23.7 | 25.1 | 26.8 | 27 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Working Cap Days ⓘ | 47 | 71 | 67 | 95 | 133 | 176 | 197 | 211 | 221 | 225 | 187 |
| Cash Conv. Cycle ⓘ | -49 | -68 | -51 | -19 | 33 | 112 | 115 | 94 | 98 | 115 | 155 |
Sales growth is growing at healthy rate in last 3 years 16.87%
Net Profit is growing at healthy rate in last 3 years 22.20%
Sales growth is good in last 4 quarters at 16.85%
Return on Equity has declined versus last 3 years average to 20.70%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 39.9 | 64.9 |
| TTM Sales (₹ Cr.) | 666 | 1,831 |
| BVPS (₹.) ⓘ | 201.9 | 334.5 |
| Reserves (₹ Cr.) ⓘ | 1,520 | 2,527 |
| P/BV ⓘ | 9.66 | 5.83 |
| PE ⓘ | 48.85 | 30.05 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 1179.95 / 2175.00 |
| All Time Low / High (₹) | 0.18 / 2175.00 |
| Market Cap (₹ Cr.) | 14,832 |
| Equity (₹ Cr.) | 15.2 |
| Face Value (₹) | 2 |
| Industry PE ⓘ | 43 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Jun'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 252 | 239 | 402 | 540 | 649 | 863 | 1,061 | 1,269 | 1,467 | 1,694 |
| Operating Expenses ⓘ | 192 | 175 | 277 | 345 | 417 | 603 | 737 | 875 | 1,026 | 1,143 |
| Manufacturing Costs | 25 | 22 | 38 | 48 | 57 | 83 | 86 | 103 | 117 | 151 |
| Material Costs | 136 | 121 | 185 | 238 | 289 | 413 | 472 | 558 | 663 | 724 |
| Employee Cost | 18 | 18 | 30 | 38 | 46 | 67 | 102 | 115 | 136 | 143 |
| Other Costs ⓘ | 14 | 14 | 24 | 21 | 25 | 40 | 77 | 99 | 110 | 125 |
| Operating Profit ⓘ | 60 | 64 | 125 | 195 | 232 | 260 | 324 | 395 | 441 | 551 |
| Operating Profit Margin (%) | 23.7% | 26.9% | 31.1% | 36.2% | 35.7% | 30.1% | 30.6% | 31.1% | 30.0% | 32.6% |
| Other Income ⓘ | 3 | 4 | 10 | 13 | 19 | 41 | 28 | 39 | 57 | 67 |
| Interest ⓘ | 1 | 0 | 1 | 1 | 1 | 0 | 2 | 1 | 1 | 1 |
| Depreciation ⓘ | 8 | 7 | 13 | 19 | 23 | 32 | 37 | 47 | 45 | 53 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 53 | 60 | 121 | 188 | 227 | 269 | 314 | 386 | 451 | 564 |
| Tax ⓘ | 12 | 14 | 25 | 44 | 50 | 54 | 62 | 77 | 74 | 103 |
| Profit After Tax | 41 | 46 | 96 | 145 | 177 | 215 | 251 | 308 | 377 | 461 |
| PAT Margin (%) | 16.3% | 19.2% | 23.8% | 26.8% | 27.2% | 24.9% | 23.7% | 24.3% | 25.7% | 27.2% |
| Adjusted EPS (₹) | 5.4 | 6.1 | 12.7 | 19.2 | 23.3 | 28.4 | 32.0 | 39.6 | 49.6 | 60.2 |
| Dividend Payout Ratio (%) | 18% | 20% | 12% | 10% | 9% | 9% | 9% | 10% | 9% | 8% |
| PARTICULARS | Jun'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 93 | 127 | 225 | 361 | 626 | 938 | 1,171 | 1,468 | 1,865 | 2,301 |
| Share Capital ⓘ | 15 | 15 | 15 | 15 | 51 | 90 | 90 | 90 | 90 | 90 |
| Reserves ⓘ | 78 | 111 | 210 | 345 | 575 | 849 | 1,081 | 1,379 | 1,775 | 2,212 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 9 | 18 | 26 | 27 | 31 |
| Debt | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 |
| Long Term Debt | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 |
| Trade Payables | 42 | 56 | 79 | 94 | 60 | 64 | 89 | 156 | 153 | 209 |
| Others Liabilities ⓘ | 93 | 84 | 54 | 45 | 56 | 114 | 87 | 79 | 130 | 143 |
| Total Liabilities ⓘ | 229 | 267 | 358 | 500 | 743 | 1,126 | 1,364 | 1,730 | 2,177 | 2,686 |
Fixed Assets | ||||||||||
| Gross Block | 143 | 181 | 195 | 232 | 272 | 355 | 423 | 446 | 480 | 702 |
| Accumulated Depreciation | 30 | 37 | 43 | 62 | 45 | 82 | 117 | 159 | 201 | 250 |
| Net Fixed Assetsⓘ | 113 | 144 | 152 | 169 | 227 | 273 | 305 | 287 | 280 | 453 |
| CWIP ⓘ | 31 | 0 | 3 | 15 | 10 | 20 | 14 | 18 | 221 | 117 |
| Investmentsⓘ | 0 | 0 | 17 | 47 | 70 | 61 | 11 | 89 | 281 | 376 |
| Inventories | 14 | 19 | 22 | 28 | 37 | 238 | 179 | 227 | 288 | 363 |
| Trade Receivables | 6 | 8 | 33 | 126 | 160 | 229 | 279 | 317 | 394 | 543 |
| Cash Equivalents | 45 | 68 | 93 | 79 | 153 | 223 | 438 | 463 | 493 | 553 |
| Others Assetsⓘ | 20 | 27 | 37 | 35 | 86 | 82 | 136 | 329 | 220 | 282 |
| Total Assets ⓘ | 229 | 267 | 358 | 500 | 743 | 1,126 | 1,364 | 1,730 | 2,177 | 2,686 |
| PARTICULARS | Jun'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 50 | 42 | 68 | 66 | 83 | 45 | 269 | 337 | 271 | 318 |
| PBT ⓘ | 53 | 60 | 121 | 188 | 227 | 269 | 314 | 386 | 451 | 564 |
| Adjustment ⓘ | 6 | 4 | 9 | 15 | 19 | 7 | 23 | 30 | 12 | 2 |
| Changes in Working Capital ⓘ | 2 | -5 | -38 | -100 | -120 | -177 | -2 | 2 | -104 | -139 |
| Tax Paid ⓘ | -12 | -16 | -24 | -36 | -43 | -55 | -66 | -81 | -88 | -109 |
| Cash Flow From Investing Activity ⓘ | -23 | -6 | -36 | -69 | -100 | -55 | -29 | -377 | -218 | -320 |
| Capex | -25 | -8 | -25 | -49 | -65 | -77 | -73 | -91 | -193 | -146 |
| Net Investments | 0 | 0 | -17 | -27 | -20 | 10 | 24 | -200 | -49 | -93 |
| Others ⓘ | 3 | 2 | 6 | 7 | -15 | 13 | 20 | -85 | 25 | -81 |
| Cash Flow From Financing Activityⓘ | -9 | -14 | -7 | -12 | 90 | 80 | -24 | -41 | -28 | -38 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | -1 | 0 | 0 | 0 | 0 | 0 | -19 | -17 | 0 | 0 |
| Interest Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | -2 | -1 | -1 | -1 |
| Dividend Paid ⓘ | -7 | -14 | -6 | -11 | -15 | -33 | -3 | -23 | -30 | -34 |
| Others ⓘ | 0 | 0 | 0 | 0 | 105 | 113 | 0 | -1 | 3 | -3 |
| Net Cash Flow ⓘ | 19 | 23 | 25 | -14 | 73 | 70 | 215 | -81 | 26 | -40 |
| PARTICULARS | Jun'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 55.78 | 43.13 | 54.97 | 49.43 | 37.14 | 29.58 | 25.65 | 24.77 | 23.68 | 22.97 |
| ROCE (%) | 71.11 | 55.41 | 69.03 | 64.08 | 45.59 | 33.35 | 28.82 | 28.77 | 26.85 | 26.92 |
| Asset Turnover Ratio | 1.23 | 0.96 | 1.28 | 1.26 | 1.04 | 0.92 | 0.85 | 0.82 | 0.75 | 0.7 |
| PAT to CFO Conversion(x) | 1.22 | 0.91 | 0.71 | 0.46 | 0.47 | 0.21 | 1.07 | 1.09 | 0.72 | 0.69 | Working Capital Days |
| Receivable Days | 4 | 10 | 19 | 54 | 80 | 82 | 87 | 86 | 88 | 101 |
| Inventory Days | 17 | 25 | 19 | 17 | 19 | 58 | 72 | 58 | 64 | 70 |
| Payable Days | 98 | 147 | 133 | 132 | 98 | 55 | 59 | 80 | 85 | 91 |
Caplin Point Laboratories was established in 1990 to manufacture a range of ointments, creams and other external applications. The Company was listed in 1994; the IPO proceeds were deployed in a manufacturing facility in Pondicherry. The promoters exposed their lives to physical risk when they ventured into war-affected countries more than two decades ago. The Company ventured into the emerging markets of West Africa, Latin America and The Caribbean to market finished formulations. The Company’s asset-light marketing business model has helped generate the resources to build world-class infrastructure.
The success of Caplin Point is primarily attributed to its unique business model. Starting of as an SME, Caplin Point decided at an early stage that the conventional style of exports would mean diminishing margins and reduced opportunities for expansion, and had taken the unique step of creating last mile logistical solutions for its exclusive distributors across Latin America and various parts of Africa. This way, Caplin Point is able to generate adequate revenue and cash flow to remain debt-free with benchmark receivables, and also continue to invest in state of the art manufacturing facilities from internal accruals. One of the main reasons for the success can be attributed to the wide range of products offered across diverse geographies.
Business area of the company
Caplin Point is the mid-sized company in India’s pharmaceutical sector to be engaged in the manufacture of APIs, finished formulations, research & development, clinical research, frontend generic presence in Latin America, brand marketing in Francophone Africa and an USFDA approved injectable facility.
Products
Awards and recognitions
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
